Context: Adrenal insufficiency (AI) requires lifelong glucocorticoid (GC) replacement. Conventional therapies do not mimic the endogenous cortisol circadian rhythm. Clock genes are essential components of the machinery controlling circadian functions and are influenced by GCs. However, clock gene expression has never been investigated in patients with AI.
with a peak during night rest and a nadir during daily activity. This pattern is the net balance of release from the hematopoietic niche and extravasation to peripheral tissues and is regulated by clock-controlled gene expression of bone marrow-stimulating factors, endothelial adhesion molecules, and migratory cytokines.
The circadian control of immune cells, both via intrinsic local mechanisms and via cortisol fluctuations, allows the organism to anticipate daily changes in activity, when the risk of antigen exposure is higher, and favors repair at night when the risk is lower (2) . However, the pharmacokinetics of standard oral glucocorticoid (GC) replacement therapies make it impossible to precisely mimic cortisol's physiologic circadian rhythm. The nonphysiologic multiple peaks and troughs of cortisol levels occurring with the immediate-release hydrocortisone distributed during the day may disrupt peripheral clock machinery, because cortisol acts as a robust endogenous zeitgeber synchronizing the central and peripheral clocks in many tissues (3) .
A once-daily modified-release hydrocortisone formulation has been developed combining an immediaterelease coating with an extended-release core that avoids the multiple peaks and troughs of standard therapies, providing a more physiologic cortisol rhythm (4) . Previous studies have shown that this formulation can improve cardiovascular risk factors, glucose metabolism, and quality of life (4, 5) . The recent Dual Release Hydrocortisone vs Conventional Glucocorticoid Replacement in Hypocortisolism (DREAM) trial showed that patients with adrenal insufficiency (AI) have an altered immune profile with an atypical inflammation characterized by more classic monocytes and impaired innate immune responses related to a shedding of CD16 from natural killer cells (6) . Evidence of immune function dysregulation was already known from the report by Bancos et al. (7) , consistent with epidemiological data describing frequent infections in patients with AI (8) (9) (10) (11) (12) .
The DREAM trial revealed that patients randomly assigned to receive once-daily modified-release hydrocortisone therapy ("switch" treatment group) had an improved circulating immune cell profile and inflammatory status and a lowered number of infections compared with subjects on standard multiple-times-a-day GC (6) . The peculiar clinical and molecular findings of the DREAM trial, and the time course of metabolic and immune changes, suggested that they were probably the results of a modification in the circadian cortisol rhythm, but a formal demonstration requires analysis of the expression of circadian genes. It is indeed known that GCs can acutely alter the oscillation of several clock-related genes by phase shifting their expression in peripheral tissues (acute stressor); however, whether the timing of GC administration delivered chronically affects clock gene expression in patients with AI has never been investigated.
In the population of the DREAM trial, we have therefore tested whether: the morning expression of circadian genes in peripheral blood mononuclear cells (PBMCs) is altered in patients with AI compared with controls; whether the observed proinflammatory state and weakened defense of patients with AI receiving conventional GC replacement therapy can be related to a dysregulation of circadian gene expression; whether the "broken clock" can be recovered by switching to a more physiologic timing of GC administration; and whether restoration of clock gene expression correlated with clinical outcomes.
Methods

Study design and participants
The rationale, design, inclusion and exclusion criteria, and results of the DREAM trial have been extensively reported elsewhere (6) . Briefly, DREAM was a randomized, two-arm, outcome assessor-blinded (independent), active comparator, controlled clinical trial enrolling 89 patients with AI and 25 adrenally sufficient age-, sex-, and body mass index (BMI)-matched controls. Patients with AI were randomly assigned to either continue usual multiple daily doses of conventional GCs (standard treatment group) or switch to an equivalent dose of once-daily modified-release hydrocortisone (switch treatment group), and 25 controls were assigned to nonintervention. Patients allocated to once-daily, modified-release hydrocortisone (Plenadren ® ; Shire, Brussels, Belgium) were instructed to take the dose on waking, before leaving bed. Patients previously on multiple doses of hydrocortisone a day received the same total daily dose, whereas patients previously on cortisone received 0.8 mg of hydrocortisone per 1 mg of cortisone. All patients provided written informed consent, and the trial was approved by the local review board at Sapienza University, conducted in accordance with the Declaration of Helsinki, and performed between March 2014 and June 2016. For the current analyses (tertiary endpoint of the DREAM trial), only patients providing an additional informed consent for gene expression profiling were included. Of the 89 enrolled patients with AI, 65 patients (73%) provided consent to gene analysis, along with 18 of the 25 (72%) adrenally sufficient controls. The acceptance rate to donate tissue for genetic research was consistent with current trends (13) . All participants underwent blood sampling in the morning between 8:00 AM and 9:00 AM, after an overnight fast (patients had to take their usual morning dose 2 hours before blood sampling) for immunophenotyping of PBMCs, as previously described (6) . For 2 weeks before the start of the investigation, all study participants maintained stable sleep schedules, including a single 8-hour nighttime sleep episode and restricting naps. The prestudy sleep schedule was based on participants' reported habitual sleep times and durations. For all participants, habitual sleep durations reported during the recruitment phase ranged between 7 and 9 hours.
with an Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA) followed by a DNase digestion step to remove genomic DNA contamination. Total RNA concentration was quantified with a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and purity estimated by 260 nm/280 nm absorption. Of the 83 patients consenting to gene expression profiling, 26 patients with AI of the switch treatment group, 29 patients with AI of the standard treatment group, and 16 controls met the sample quality criteria (absorbance 260/280 ratios between 1.9 and 2.2, RNA concentrations $20 mg/mL, with integrity assessed by gel electrophoresis) (Fig. 1) .
We reverse transcribed 2 mg of RNA from each sample by using iScript Reverse Transcription Kit (Bio-Rad). The total cDNA pool obtained served as the template for subsequent PCR amplification in a real-time PCR assay predesigned 96-well panel for use with SYBR ® Green circadian rhythms (SAB target list) H96 (PrimePCR ® ; Bio-Rad). PrimePCR ® is a preoptimized assay designed to guarantee high assay specificity, compatibility, avoidance of secondary structures, primer annealing sites, and snips in the target region, maximized detection of transcript isoforms, fully validated for the human genome, which we found particularly indicated for clinical trials because it is easily reproducible and yields comparable data. Primers (including housekeeping genes) were lyophilized in each well, through the use of SsoAdvanced TM Universal SYBR ® Green Supermix. The quantitative reverse transcription polymerase chain reaction was run on CFX Connect (Bio-Rad). In addition to the 84 genes tested, each plate contained housekeeping genes for quantitative analyses (GAPDH, ACTB, HPRT1, B2M) and specific controls for genomic DNA contamination, RNA quality, and efficiency. Only assays that passed internal controls were included in the database. For data analysis, the Cq expression of housekeeping genes was tested by CFX Manager™ software (Bio-Rad) to identify the most stable reference gene based on geometric mean of expression. Most of the reference genes passed the test, with GAPDH and ACTB being the most stably expressed among samples and thus selected for normalization. All gene expression results are expressed as relative expression level normalized against housekeeping genes.
Statistical analysis
The statistical plan of the study has been previously reported (6) , and the full prespecified plan is available online (https:// web.uniroma1.it/dip_dms/ricerca/trials-clinici). Briefly, efficacy analyses were based on an intention-to-treat approach. Normality of distribution was assessed by Shapiro-Wilk test. The estimated treatment differences (ETDs) in the change from baseline to week 12 were analyzed with an analysis of covariance (ANCOVA) model that included baseline outcome as a covariate and treatment as a fixed effect. Additional covariates included were sex, BMI, age, smoking, type and duration of AI, diabetes mellitus, and white blood cell count. The ANCOVA model used the last-observation-carried-forward principle and provided the least squares mean estimates, with 95% CI adjusted for multiple comparisons. Standardized residuals were tested for normality via Shapiro-Wilk test. Homoscedasticity and homogeneity of variances were assessed by visual inspection and Levene test. Multicollinearity was assessed by a variance inflation factor. Two levels of evidence were required for investigated genes to be considered clinically relevant: a differential expression at baseline between patients with AI and controls, and a significant ETD between randomization groups. Subgroup analysis was carried out reporting the significance of the treatment by subgroup interaction. Because of the risk of false discoveries in multiple testing, adjusted P values were also calculated for ETD through the modified BenjaminiHochberg approach (14) , with a value of ,0.05 regarded as significant. The study was registered at clinicaltrials.gov with identifier NCT02277587.
Results
Overall, 83 subjects consented to gene testing, and 71 had a full gene expression analysis carried out on PBMCs freshly isolated in the morning at baseline and 12 weeks after randomization: 29 patients with AI assigned to the standard treatment group, 26 patients with AI to the switch treatment group, and 16 healthy controls to nonintervention follow-up (Fig. 1) .
Baseline characteristics were comparable between AI groups (switch vs standard), whereas controls had lower BMI and lipid levels (total/high-density lipoproteincholesterol and triglycerides) ( Table 1 ). The total daily dose of GCs was well balanced between patient groups at randomization and was not different at study end. Gene expression data at baseline are shown in Supplemental Table 1 and Supplemental Fig. 1 . The clinical features of all patients with AI enrolled in the main trial, those who consented to gene expression profiling, and those who passed quality control for gene analysis were similar, except for a higher prevalence of primary AI in the group consenting to the analysis, and consequently a lower BMI, compared with those who did not, but there were no other differences in the metabolic, immune, or infection data, suggesting that the current subgroup is representative of the outcomes of the main trial (Supplemental Table 2 ).
The expression of circadian genes was quantified relative to the housekeeping genes through the PrimePCR ® circadian rhythms pathway assay in CFX Manager™ software. Of the 84 genes included in the panel, 68 were found to be expressed in the majority of samples.
At baseline, 19 genes displayed a statistically different level of expression in PBMCs drawn from healthy (24) (25) (26) (27) (28) Gene expression data at baseline in the two groups are reported in Supplemental Table 1 .
Abbreviations: BID, two times daily; OD, once daily; TID, three times daily. a Values are expressed as mean (lower-upper limit of 95% CI), median (25th; 75th percentile), count (n), or percentages (%) as appropriate.
controls vs subjects with AI ( Fig. 2 and Supplemental  Fig. 1 ). Global inspection of the panel revealed a generalized downregulation (from black to green) of clock-controlled gene expression in patients with AI, consistent with a flattening of the endogenous oscillators. The estimated marginal differences in the relative expression are shown in Fig. 2A . In the CLOCK gene cluster, ARNTL [BMAL1] (P , 0.001) and CLOCK (P , 0.001) were found to be downregulated, whereas PER3 (P = 0.013) and TIMELESS (P = 0.005) were upregulated in patients with AI compared with controls. The CREB pathway cluster was deeply affected, with most genes underexpressed in patients with AI: CAMK2D (P = 0.001), CREB1 (P , 0.001), CREB3 (P = 0.012), MAPK1 (P = 0.007), PRKAR1A (P = 0.003), PRKAR2A (P , 0.001), and PRKCB (P = 0.003), whereas AANAT (P = 0.009) and MAT2A (P = 0.008) appeared marginally increased in patients with AI compared with controls ( Fig. 2B) . Among the remaining genes, baseline differences were found in transcription factors with upregulated SP1 (P , 0.001) and downregulated WEE1 (P = 0.001; Fig. 2C ) and in the casein kinase gene group, with upregulated CSNK1A1 (P , 0.001) and CSNK1E (P = 0.033) and downregulated ONP3 (P = 0.037) and PRF1 (P , 0.001) (Fig. 2D) . The relative expression of several genes correlated with the metabolic and immune phenotype of the entire study population (Supplemental Table 3 ), showing that overexpression and underexpression of circadian genes including WEE1, TIMELESS, PRF1, and PER3 are associated with the increased CD16 shedding, ADAM17 levels, inflammatory monocytes, and ultimately metabolic derangement and susceptibility to infections. Most genes did not display differential levels of expression when we compared primary and secondary AI at baseline, except for ONP3, which was significantly suppressed in primary AI only (Supplemental Table 4 ). At week 12, switching to once-daily modified-release hydrocortisone robustly modulated the relative expression of 22 genes when compared with patients randomly assigned to multiple-daily-dose standard treatment after adjustment for multiple comparisons (Table 2 , Fig. 3 , Supplemental Table 5 , and Supplemental Fig. 2) . Specifically, the once-daily switched treatment increased ARNTL, ARNTL2, CLOCK, and RORA expression (Fig. 3) and reduced the previously overexpressed PER3 and TIMELESS levels. The ETD between the intervention groups in the CREB signaling cluster consisted in a significant reduction of AANAT and MAT2A and a significant increase in CAMK2D, CREB1, CREB3, MAPK1, PRKAR1A, PRKAR2A, and PRKCB (Fig. 3) .
Regarding the other circadian regulated genes, a significant ETD was found for SP1 and WEE1, which were inversely modulated; for CSNK1A1, which was downregulated; and for the three upregulated genes GUSB, ONP3, and PRF1 (Fig. 3) .
Of the 19 genes that were differentially modulated at baseline when we compared subjects with AI with control subjects, all but one (CSNK1E) were affected by treatment allocation (Fig. 3) , thus matching the two prerequisites for relevance: a differential expression at baseline compared with healthy controls and a significant treatment difference between randomization groups. For all 18 genes the modulation was toward the level of expression found in healthy controls, that is, toward normalization. However, a significant ETD was found for another four genes that were not found modulated at baseline (ARNTL2, GUSB, PRKR2B, and RORA) (Supplemental Fig. 3 ). Subgroup analysis revealed no treatment by subgroup interaction for any of the modulated genes (Supplemental Table 6 ), suggesting that the effects of treatment switch were independent of the underlying etiology of the AI. Because treatment allocation produced a shift in the phenotype of some subsets of circulating PBMCs, namely a reduction in CD14 + CD16 2 and an increase in CD16 + CD56 + CD3 2 cells (6), we also investigated gene expression in the subset that remained stable during the trial, the CD3 + T lymphocytes, which were unaffected by treatment. Of the 19 differentially expressed genes, 16 were also modulated in lymphocytes sorted from the entire set of PBMCs pooled according to treatment allocation (Supplemental Figure 4) . Significant correlations were found between the change in several clock gene expression and the change in clinical outcomes including the glycated hemoglobin, blood pressure, levels of circulating soluble CD16, ADAM17, classic proinflammatory monocytes, and ultimately the frequency of infections ( Table 3 ), suggesting that the extent of reprogramming of circadian gene expression can be linked to the magnitude of improvement in clinically measurable outcomes.
Discussion
The DREAM trial was a head-to-head comparison of standard twice-or thrice-daily cortisone or hydrocortisone and once-daily modified-release hydrocortisone replacement therapy. We showed that patients with AI on standard replacement therapy exhibit unexpected abnormalities in circulating PBMCs, with more classic monocytes and a smaller number of CD16 + natural killer cells, that can be partially reversed by changing the timing of GC administration (6) .
In the current report we showed that the patients with AI on standard replacement therapy have an abnormal expression of clock-related genes in circulating blood cells that can be partially normalized by switching from a multiple-times-a-day to a once-daily modified release hydrocortisone administration. To our knowledge, this is the first report of a link between the chronopharmacology of GC administration, the expression of circadian genes in immune cells, and the metabolic outcomes in the context of a clinical trial Although the influence of GCs on immune trafficking and regulation is known (15) , recent studies suggest that GC administration, or adrenalectomy, affects the expression of clock-related genes, and, in turn, the complex CLOCK/ARNLT can suppress GC receptor-induced transcriptional activity (16) . The rhythm of peripheral CLOCK gene expression shifts the activity of the GC receptor out of phase to when GC peaks in blood (17) , setting an additional feedback to prevent overexposure to GCs (16) . Conversely, when the clock is downregulated, GC sensitivity is higher. The latter is consistent with the knowledge of more deleterious metabolic effects of GC administered late in the evening (18) . The importance of time exposure as compared with dose exposure has been recently confirmed in animal studies showing that high peaks of GC are well tolerated as long as sufficiently long "off" intervals are preserved (19) .
In addition to metabolic regulation (20) , canonical CLOCK components are also involved in immune modulation (21) . Patients with AI, even when treated according to the best practice guidelines, have higher mortality and hospitalization rates, especially from infectious and cardiovascular diseases (8-12, 22, 23) . The DREAM trial (6) confirmed previous observations (7) that patients with AI can suffer from defective innate immunity with an "exhausted phenotype" of natural killer cells. Clock gene dysregulation may lead to functional hypercortisolism or hypocortisolism in peripheral target tissues (24) , highlighting the fact that estimating total cortisol exposure is more complex than just measuring circulating cortisol levels (25) .
In this study we found that, compared with adrenally sufficient controls, patients treated with standard GC therapy showed a significant downregulation of canonical CLOCK components, such as the CLOCK gene, which encodes for the Circadian Locomotor Output Cycles Kaput (CLOCK) protein and aryl hydrocarbon receptor nuclear translocator (ARNTL, BMAL), which could be restored to normal by altering the timing of GC administration. Moreover, the GC switch restored CSNK1A1 and PRF1 expression to levels correlated with the treatment-induced reduction in HbA1c, confirming the importance of the timing of GC administration for metabolic function. A recent study in mice showed that raising the peak of the GC oscillations up to 40-fold by injecting corticosteroids for 21 days produced no relevant increase in adipogenesis, as long as GC were given in the correct circadian periods, whereas losing the nadirs or "off periods" of GC administration produced a striking increase in adipogenesis (19) . Interestingly, we found PER3 upregulated and correlated with inflammation in patients with AI. Recent evidence supports a prominent role for PER3 oscillation, as compared with PER1, in adipose tissue function (26) .
We found a significant downregulation of WEE1 in patients with AI at baseline, inversely related to BMI and triglycerides. Interestingly, WEE1 is the transcriptional factor that appears to coordinate the transition between DNA replication and mitosis by arresting G2 phase and inhibiting progression toward mitosis. Consequently, reduced WEE1 synthesis favors entry into mitosis and may even shorten its duration. Downregulated WEE1 has also been found in pituitary adenomas, suggesting a potential role in tumorigenesis of the loss of its protective function (27) . WEE1 expression is controlled by CLOCK-ARNLT (28) , and in our study it was restored in the switch treatment group after 12 weeks. Interestingly, the upregulation of WEE1 in the switched treatment group correlated with a reduction in glycated hemoglobin and inflammatory monocytes.
The cAMP-responsive element-binding protein, known as CREB/CRE, plays a crucial role in several cell functions, including proliferation, survival, differentiation, adaptive responses, glucose homeostasis, spermatogenesis, synaptic plasticity associated with memory, and circadian rhythms (29) . CREB is induced by a variety of growth factors and inflammatory signals; it can also promote anti-inflammatory immune responses, such as the inhibition of NF-kB activity, the induction of IL-10, and the generation of Treg, and promotes activation and proliferation of T and B lymphocytes (30) . We found a significant downregulation in most cAMP downstream targets (CREB1, PRKAR1A, and PRKAR2A) in patients with AI compared with controls, a finding consistent with the recurrent infections seen in patients with AI. Accordingly, PRF1, the predominant cytolytic protein secreted by natural killer cells (31) , was also found downregulated in patients with AI compared with controls. Of note is that PRF1 null mice exhibit increased body weight and adiposity, glucose intolerance, and insulin resistance caused by an M1-polarization of b Systolic blood pressure.
c Diastolic blood pressure.
d Log 10 (ADAM17) and log 10 (CD16s).
e Total infection score.
f P , 0.05.
macrophages infiltrating visceral adipose tissue (32) . We found that restoration of PRF1 to control levels in patients with AI in the switched treatment group correlated with a reduction in HbA1c. Taken together, our findings on PRF1 and PER3 modulation support a role for adipocyte dysfunction in explaining the metabolic impairment and low-grade inflammation observed in patients with AI on multiple-times-a-day GC treatment. The latter could also explain the higher risk of atherosclerosis in these patients in the absence of fat accumulation (33) . An upregulated expression of AANAT was also observed in patients with AI at baseline, with a significant reduction in the switched treatment group at 12 weeks. AANAT encodes for arylalkylamine N-acetyltransferase, also known as the "Timenzyme," which controls daily changes in melatonin production by the pineal gland. AANAT is also expressed in the retina, where it may play other roles, including neurotransmission and detoxification (34) . Melatonin peaks at night, swiftly decreasing in the morning after light exposure; AANAT follows the same pattern. We found ANAAT overexpressed in the morning in patients with AI under standard therapy (measured 2 hours after awakening). The lack of response (i.e., expression decrease) to a strong zeitgeber, such as daylight, observed in our patients provides insights on the detrimental effect of a nonphysiologic GC profile on the entire circadian machinery (35) .
The altered expressions of selected genes with a pivotal role in metabolism and innate immunity were all reversed to near normal when patients with AI switched from the standard multiple-times-a-day regimen to the once-daily modified-release hydrocortisone. Although the ETD between the two regimens could be artifactual and not necessarily linked to a clinical outcome, the fact that the postswitched gene analysis was more similar to that of controls (who are not taking exogenous GCs) suggest that the more physiologic replacement is the main cause for the entrainment of circadian genes. Finally, the correlation between the change in clinical variables (glycated hemoglobin, infection score, sADAM17, and sCD16) and the modulation in gene expression profile suggests that CAMK2D, CSNK1A1, GUSB, ONP3, PER3, PRF1, SP1, TIMELESS, and WEE1 are causally linked to the clinical outcomes observed in the main DREAM trial report (6) .
The current study has several advantages but also some limitations. Advantages include the random allocation, blinding of the assessors, strict inclusion criteria, non-crossover design, high number of circadian genes simultaneously evaluated in both nonpooled and pooled samples, and inclusion of a control group. The main limitation was the single-time evaluation for circadian gene expression. However, the presence of a control group, the standardization of timing and type of therapy, and the modality of sample collection increase the value of our results. Another limitation is that the two regimens can lead to a different total GC exposure, and some of the effects occur via GC-mediated activation of the mineralocorticoid receptor in monocytes (36, 37) . A third limitation is that our study did not include protein analysis, requiring an abundant source material difficult to store in the context of a clinical trial, thus limiting functional relevance of the observed findings. Finally, some of the differences in expression of some genes observed in patients with AI could be related to the change in PBMC populations. To evaluate this aspect, we normalized gene expression through housekeeping genes and performed a pooled analysis on the T lymphocyte subset that remained stable among study groups throughout the trial. However, such analyses cannot be considered conclusive, and to address this complex biological bias newly designed studies are necessary, such as the use of single-cell approach analysis.
In conclusion, cortisol acts as crucial synchronizer of the expression of several circadian genes. In AI, the multiple-times-a-day administration of GCs, as occurs with the standard replacement schemes, causes a desynchronization of the endogenous and exogenous zeitgebers that can be measured as a flattening of the oscillator in PBMCs (Supplemental Fig. 5 ). Switching to a once-daily regimen allows better entrainment of exogenous administration and endogenous clocks, particularly to CLOCK/ BMAL-and CREB-related genes. The resynchronization correlates with clinical improvement. This study shows that assessment of the peripheral circadian oscillators in PBMCs offers a tool to elucidate clinical disorders related to circadian rhythm disruption, such as metabolic syndrome and malignancies in night-shift workers. A deeper knowledge of the role of the molecular clock misalignment in adrenal disorders will enable development of better treatment strategies.
